Recent Updates
Recently added Catalysts

Airway Bypass

Phase 1

Emphysema or COPD | Unknown | Respiratory |Catalyst Pharmaceuticals, Inc.|Last Updated: Feb 8, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06249529Airway Bypass - Safety and Feasibility StudyEARLY_PHASE1 RECRUITING 10Jan 26, 2024Jun 1, 2026Feb 8, 20241 Georgia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Adverse Events
12 Months

including but not limited to device-related blood vessel perforation, pneumothorax, COPD exacerbation, device migration, device removal, rehospitalization.

Secondary Endpoints
Implant Success
0 Days
Procedural success
1 Days
CAT
12 Months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
InterventionalEXPERIMENTALPatients in the interventional arm will receive implant of one or more airway bypass devices.
Interventions
NameTypeDescription
Airway BypassDEVICEBypass stent(s) are implanted to allow air trapped in the parenchyma to escape
Unlock Study Design Details
Eligibility Criteria
Age Range50 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Patient between 50 to 80 years old. 2. High Resolution CT scan indicates severe emphysema. 3. Patient has post- bronchodilator FEV1 less than or equal to 50% of predicted. 4. Total Lung Capacity \>100% of predicted. 5. Residual volume ≥225 % of predicted. 6. RV/TLC \>0.69 7. ...

Countries:Georgia
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06249529studyFirstPostDate: changed